Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Crohn Disease with curative ileocolonic resection~* Randomization within 45 days from ileocolonic resection or end or loop ileostomy within last year and closure occurred within 45 days from randomization~* Fecal stream restoration at least 14 days prior to randomization~* Presence of at least one risk factor for recurrence~* Pregnancy protection on board during the study for childbearing female subjects~Exclusion Criteria:~* Presence of CD proximally or distally to the site of resection~* Patients with strictureplasties at index surgery or ileorectal anastomosis~* patients with active perianal CD~* Patient treated with other treatments usually utilised for CD~* Patients with active diseases with gastrointestinal involvement~* intestinal obstruction or pseudo-obstruction~* Patients presenting diarrhoea plus fever or bloody stools~* Positivity to clostridium difficile toxin~* Severe hepatic or renal impairment~* Presence of severe cardiac insufficiency~* Hypersensitivity to rifamycin antimicrobial agents~* other conditions that would interfere or prevent the study completion~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin delayed release tablets (Type: EXPERIMENTAL): Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo tablets twice a day for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).